Recent studies have reported that RNAi-mediated silencing of CTGF or treatment with a specific antibody (pamrevlumab) in combination with pemetrexed, a single agent regimen in elderly mesothelioma patients, is effective for mesothelioma tumor suppression [11, 13]. Here, CCN2 is linked to mesothelioma.